Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD
Key facts
- Who runs it
- Yan'an Affiliated Hospital of Kunming Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 31 Mar 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional
- Treatments tested
- Hybrid TEVAR combined with long bare-metal stent intervention
- Record updated
- 25 March 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- ≧18 years old, ≦80 years old
- Acute phase with a course of disease ≦14 days
- CTA confirmed diagnosis of active dissection type B in accordance with the Stanford classification in the ESC guidelines, and requiring TEVAR surgery
- For patients with acute non-type A and non-type B aortic dissection involving the left subclavian artery: current technologies (such as fenestration, single branch, chimney, etc.) can be used to solve the reconstruction of the left subclavian artery
- The distal end of the dissection exceeds the renal artery plane
- Signed informed consent (emergency waiver applicable), with primary intervention using CTAG devices. Adjunctive procedures may include LSA revascularization, percutaneous fenestration, aortic/peripheral stenting, surgical fenestration, or bypass grafting
- Medical record completeness >90% with mandatory CTA data
- Protocol compliance including follow-up adherence
Who cannot take part
- Major aortic surgery within 30 days prior (except LSA revascularization)
- Participation in other device/drug trials within 1 year
- Traumatic TBAD, intramural hematoma, or penetrating aortic ulcer
- Complete thoracic aortic thrombosis pre-TEVAR
- Known device material hypersensitivity
- Systemic infection increasing endograft infection risk
- Evidence of aortic infection
- Connective tissue disorders (e.g., Marfan syndrome)
- Renal failure: Baseline serum creatinine >2.5 mg/dL (high-risk for contrast nephropathy)
- Dissection termination above renal arteries
- Iliofemoral stenosis/angulation precluding endovascular access
- Non-diagnostic CTA image quality
- Indeterminate symptom onset time
- Re-intervention within 12 months post-TEVAR for non-aortic indications
- Bowel necrosis from visceral ischemia
- Moribund status: ASA class 5 with <24h life expectancy
- Refractory shock (SBP <90 mmHg)
- Pregnancy or lactation
- Active substance abuse
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this study is to evaluate the safety and efficacy of the TEVAR combined with extended bare-metal stenting (distal landing zone ≥2 cm below renal arteries) in patients with acute complicated type B aortic dissection (ATBAD).
Read full original descriptionShow less
Additionally, to prevent postoperative true lumen hypoperfusion in residual thoracoabdominal aortic dissection (visceral zone, infrarenal aorta, and iliac arteries) and persistent ischemic manifestations in visceral and lower extremity arteries post-endovascular repair, extended bare-metal stents are deployed to maintain adequate distal true lumen patency. This strategy ensures perfusion to visceral branches and lower limbs while preparing for future complete endovascular aortic repair.
The group in the trial
- Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM and Fabulous® Device Surgical ImplantTreatment being tested
Subjects with acute type B aortic dissection were treated with an endovascular procedure using the Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm Thoracic Aortic Endoprosthesis and the Fabulous® 45-150mm long big bare stent via femoral artery access. (Permanent implant)
Treatment: Hybrid TEVAR combined with long bare-metal stent intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD: a Prospective and Cohort Study
- Criteria questions
- Built from NCT06892730, who can take part
- Record updated
- 25 March 2025